Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Nestle Health Science announced an agreement to acquire Aimmune Therapeutics for approximately 2.6 billion dollars, gaining full ownership of Palforzia, the…
Nestle Health Science will pay 2.6 billion dollars for Aimmune Therapeutics in a deal that brings full ownership of Palforzia into the Swiss food giant's…
Nestle Health Science is divesting Palforzia to French allergy specialist Stallergenes Greer, closing the chapter on the 2.6 billion dollar 2020 acquisition of…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Nestle Health Science agreed to acquire Aimmune Therapeutics for $34.50/share in cash, ~$2.6B fully-diluted equity value (174% premium to 8/28 close). Brought Palforzia, the first FDA-approved peanut allergy oral immunotherapy, into Nestle Health Science. NHSc's prior ~$473M, 25.6% stake in Aimmune was rolled up.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Nestle S.A. / Aimmune Therapeutics, Inc. (this deal) | 2020 | $2.6B | — |
| Nestle S.A. / Allergan plc | 2020 | — | — |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| PerkinElmer, Inc. / EUROIMMUN Medizinische Labordiagnostika AG | 2017 | $1.3B | 88 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Roche Holding AG / Genentech, Inc. (Roche Group) | 2009 | $46.8B | 72 |
| Travere Therapeutics, Inc. / Everest Medicines Limited | 2026 | $1.1B | 72 |
← Browse all deals · How we score deals
More: 2020 deals · Immunology deals